畅脉舒治疗冠心病高粘滞血症的疗效观察

目的：探讨畅脉舒治疗冠心病的疗效机理。方法：用畅脉舒治疗冠心病且伴有高粘滞血症患者80例（治疗组），并与用复方丹参注射液加地奥心血康治疗的40例患者（对照组）进行对比，两组疗程均为30天。并对血清脂质过氧化物（LP）含量、超氧化物歧化酶（SO）活性、血脂、血液流变学等指标进行检测。结果：总有效率、心电图改善程度及伴随症状疗效治疗组均优于对照组（P＜0．05或P＜0．01）；两组患者LPO、SOD、血脂、血液流变学指标治疗后较治疗前均有明显改善（P＜0．05或P＜0．01）；LPO、SOD、血清胆固醇、低切变粘度治疗组较对照组改善则更明显（P＜0．05）。结论：畅脉舒可降低冠心病患者血液的高粘滞状态，提高抗氧化能力，并有效地改善冠心病症状。

英文摘要:

To explore the therapeutic effect and mechanism of Changmaishu (CMS) in treating coronary heart disease (CHD). Methods: Eighty patients with CHD complicated with hyperviscosity were treated with CMS for a period of 30 days as the CMS group, and the 40 patients treated with Salvia injection and Di’ao Xinxuekang were taken as the control group. The therapeutic efficacy and effect of treatment on plasma lipid peroxide (LPO) content, superoxide dismutase (SOD) activity, blood lipids, hemorrheologic indexes were observed. Results: The CMS group was better in clinical total effective rate, ECG improvement and concomitant symptoms relieved than those in the control group (P <0. 05 or P <0.01). Markedly improvement of laboratory findings occurred in both groups (P <0.05 or P <0.01), but the changes of some parameters, such as LPO, SOD, total cholesterol, low-shear blood viscosity in the CMS group were more significant than those in the control group (P < 0.05). Conclusion: CMS could reduce the blood hyperviscosity, increase antioxidative energy and improve symptoms of CHD effectively.

关闭